Skip to main content
Top
Published in: Journal of Neurology 12/2013

Open Access 01-12-2013 | Review

Multiple sclerosis in the Arabian Gulf countries: a consensus statement

Authors: Saeed Bohlega, Jihad Inshasi, Abdel Rahman Al Tahan, Abu Bakr Madani, Hussien Qahtani, Peter Rieckmann

Published in: Journal of Neurology | Issue 12/2013

Login to get access

Abstract

The epidemiology of multiple sclerosis (MS) is rapidly changing in many parts of the world. Based on the Kurtzke classification, the Arabian Gulf Region is located in a low-risk zone for MS; however, recent studies suggest a moderate-to-high prevalence nearby (31–55 MS per 10,0000 individuals), with an increase in incidence in recent years. The relapsing-remitting disease course ratio is 2.5:1 versus the primary progressive type. In a geographic area that was previously associated with low prevalence; the recent high prevalence and fast rising incidence of MS in the gulf countries, encouraged the neurologists of this region to meet in a consensus panel, in order to share our latest findings in terms of MS epidemiology and consent on MS management in the Arabian Gulf. Therefore 20 key opinion leader neurologists and MS experts representing various countries of the Arabian Gulf have met in Dubai on the 2 and 3 February 2012, they shared their latest epidemiological findings, discussed recent MS aspects in the region, and consented on MS management relevantly to this geographic area.
Literature
1.
go back to reference Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y (2005) Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 53:125–131PubMedCrossRef Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y (2005) Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 53:125–131PubMedCrossRef
3.
go back to reference Daif AK, Al-Rajeh S, Awada A, Al Bunyan M, Oqunniyi A, Abdul Jabar M, Al Tahan AR (1998) Pattern of presentation of multiple sclerosis in Saudi Arabia: analysis based on clinical and paraclinical features. Eur Neurol 39(3):182–186PubMedCrossRef Daif AK, Al-Rajeh S, Awada A, Al Bunyan M, Oqunniyi A, Abdul Jabar M, Al Tahan AR (1998) Pattern of presentation of multiple sclerosis in Saudi Arabia: analysis based on clinical and paraclinical features. Eur Neurol 39(3):182–186PubMedCrossRef
4.
go back to reference Inshasi J, Thakre M (2011) Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci 121(7):393–398PubMedCrossRef Inshasi J, Thakre M (2011) Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci 121(7):393–398PubMedCrossRef
5.
go back to reference Naeem Z (2010) Vitamin D deficiency—an ignored epidemic. Int J Health Sci 4:5–6 Naeem Z (2010) Vitamin D deficiency—an ignored epidemic. Int J Health Sci 4:5–6
6.
go back to reference Denic S, Bener A (2001) Consanguinity decreases risk of breast cancer-cervical cancer unaffected. Br J Cancer 85(11):1675–1679PubMedCrossRef Denic S, Bener A (2001) Consanguinity decreases risk of breast cancer-cervical cancer unaffected. Br J Cancer 85(11):1675–1679PubMedCrossRef
7.
go back to reference Al Jumah M, Kojan S, Al Khathaami A, Al Abdulkaream I, Al Blawi M, Jawhary A (2011) Familial multiple sclerosis: does consanguinity have a role? Mult Scler 17(4):487–489PubMedCrossRef Al Jumah M, Kojan S, Al Khathaami A, Al Abdulkaream I, Al Blawi M, Jawhary A (2011) Familial multiple sclerosis: does consanguinity have a role? Mult Scler 17(4):487–489PubMedCrossRef
8.
9.
go back to reference Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4(5):281–288PubMedCrossRef Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4(5):281–288PubMedCrossRef
10.
go back to reference Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904PubMedCrossRef Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904PubMedCrossRef
11.
go back to reference Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRef Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRef
12.
go back to reference Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397PubMedCrossRef Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397PubMedCrossRef
13.
go back to reference Zwibel H (2011) Long-term experience of glatiramer acetate (Copaxone) in the treatment of clinically isolated syndrome and relapsing-remitting multiple sclerosis. US Neurol 7(2):126–131 Zwibel H (2011) Long-term experience of glatiramer acetate (Copaxone) in the treatment of clinically isolated syndrome and relapsing-remitting multiple sclerosis. US Neurol 7(2):126–131
14.
go back to reference Ziemssen T, Schrempf W (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79:537–570PubMedCrossRef Ziemssen T, Schrempf W (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79:537–570PubMedCrossRef
15.
go back to reference Gonsette RE (2007) Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 8(8):1103–1116PubMedCrossRef Gonsette RE (2007) Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 8(8):1103–1116PubMedCrossRef
16.
go back to reference Murray TJ (2006) The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? Expert Opin Drug Saf 5(2):265–274PubMedCrossRef Murray TJ (2006) The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? Expert Opin Drug Saf 5(2):265–274PubMedCrossRef
17.
go back to reference Hartung HP (2005) Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 252(Suppl 3):iii44–iii50PubMed Hartung HP (2005) Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 252(Suppl 3):iii44–iii50PubMed
18.
go back to reference Rio et al (2011) Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 24 (3) June 2011 Rio et al (2011) Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 24 (3) June 2011
19.
go back to reference Rio J et al (2006) Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352PubMedCrossRef Rio J et al (2006) Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352PubMedCrossRef
20.
Metadata
Title
Multiple sclerosis in the Arabian Gulf countries: a consensus statement
Authors
Saeed Bohlega
Jihad Inshasi
Abdel Rahman Al Tahan
Abu Bakr Madani
Hussien Qahtani
Peter Rieckmann
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 12/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-013-6876-4

Other articles of this Issue 12/2013

Journal of Neurology 12/2013 Go to the issue